MARA vs FUTU

Capital Markets · market cap $3.7b. Down 59% from 52-week high of $23.45 — deep drawdown territory. Revenue growing +38% — in hypergrowth territory. PEG 0.10 — paying under fair value for the growth rate. 13 sell-side analysts rate this a Buy with a mean 1-yr target of $18.61 (implying +93% upside).

Financial moat — scale of deposit base / underwriting franchise plus regulatory capital advantages. The largest players compound book value through cycles that erase smaller competitors.

Down 59% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 5.35 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Balance-sheet financial — book value, net interest margin, and credit loss provisions are the lever points; a rates regime change or a deterioration in the loan book moves the stock more than EPS does.

Capital Markets · market cap $15.9b. Down 44% from 52-week high of $202.53 — deep drawdown territory. 18 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $160.85 (implying +41% upside).

Net margin 46% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 31% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Financial moat — scale of deposit base / underwriting franchise plus regulatory capital advantages. The largest players compound book value through cycles that erase smaller competitors.

Down 44% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Duration mismatch — the asset and liability books reprice on different schedules; a rapid move in rates either direction can compress net interest margin before management can reposition.